Despite major product launches from diabetes rivals last year, Abbott’s diabetes unit brought in $1.8bn total Q1 sales to ...

Continuous glucose monitoring devices could overstate blood sugar levels, with a study revealing inconsistencies in readings compared with traditional methods.

Medical device maker Abbott Laboratories maintained its annual profit forecast on Wednesday and said it expected the U.S.

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...

Investing.com - Abbott Laboratories (NYSE:ABT) has backed its full-year financial guidance despite noting a period of ...

Guidance: Abbott reaffirms full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.15, with organic sales growth ...

Biosensors market in 2025 is driven by advanced healthcare applications, dominated by oxidoreductase enzymes and non-wearable ...

As per Vantage Market Research, the Global Hba1c Testing Device Market has been significantly growing over the years due to ...

Like Johnson & Johnson did during its earnings call the day before, Abbott estimated that global tariffs would end up costing ...

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023.